Key Takeaways
- • Ireland's venture capital ecosystem contracted 58% in Q1 2026, with only €221.7 million raised across the market, yet a small cohort of mega-round companies offset broader weakness with outsized funding activity.
- • Three companies dominated Q1 2026 investment activity: Fonoa (Dublin-based AI tax operating system) secured $110 million; CameraMatics (AI-powered video telematics and fleet intelligence) raised $56 million; and Manna (drone delivery) closed a $50 million round—collectively accounting for the lion's share of capital deployed.
- • International investors captured 85% of total capital raised in Q1 2026, underscoring Ireland's reliance on foreign institutional capital and the concentration of venture funding among cross-border syndicates.
- • The VenturePulse survey documented significant medtech and biotech activity among secondary players, with Neurent Medical raising €62.5 million and Aerska securing €33 million, suggesting sector-specific strength despite aggregate market contraction.
- • Ireland's 2026 funding landscape is increasingly bifurcated, with a narrow tier of high-growth AI, logistics, and health-tech scale-ups attracting institutional capital while mid-market and early-stage companies face substantially reduced availability of venture financing.
Summary
Ireland's venture capital market entered 2026 under significant headwinds, with the Irish Venture Capital Association's VenturePulse survey revealing a stark 58% decline in capital deployment during the opening quarter. The €221.7 million raised marked a material contraction from the prior-year period, which the Association contextualized as benefiting from an abnormally strong comparative quarter. Despite this overall weakness, a concentrated cluster of high-impact scale-ups executed mega-rounds that substantially shaped headline figures and demonstrated sustained investor appetite for growth-stage companies in select sectors.
The concentration of capital among elite-tier companies was pronounced. According to KPMG's concurrent VenturePulse analysis covering the same period, 19 deals collectively raised $212.3 million; however, just three transactions accounted for the predominant share of activity. Fonoa, a Dublin-headquartered artificial intelligence tax operating system provider, secured the largest single investment at $110 million. CameraMatics, an AI-enabled video telematics and fleet intelligence platform, raised $56 million, while Manna, a drone delivery logistics company, closed a $50 million funding round. These three deals alone underscore a market structure increasingly skewed toward late-stage capital concentration in AI-adjacent and logistics automation sectors.
Secondary-tier activity revealed additional pockets of strength in specialized sectors. Neurent Medical led the medtech category with a €62.5 million raise, followed by Aerska, which secured €33 million in biotech funding. This bifurcation—where mega-rounds in AI and logistics coexist with selective strength in medtech and biotech—reflects institutional investors' strategic prioritization of high-TAM (total addressable market) technology and health-tech verticals.
A critical feature of Ireland's 2026 venture landscape is the outsized role of international capital. International investors accounted for 85% of total capital raised during Q1 2026, a dependency that highlights both the openness of Ireland's startup ecosystem to global funding flows and the limited availability of domestic institutional venture capital. This reliance on foreign institutional syndicates creates both opportunity and concentration risk for Irish scale-ups seeking Series A and later-stage financing.
The bifurcation between mega-round winners and the broader market reflects a structural shift in Irish venture financing: in an environment of constrained overall capital availability, institutional investors are consolidating capital among proven, late-stage cohorts rather than distributing capital across a broader portfolio of emerging companies. This dynamic suggests that mid-market and early-stage Irish startups outside the AI, logistics, and specialized health-tech sectors may face materially reduced access to venture capital in 2026 and beyond.
The concentration of capital among elite-tier companies was pronounced. According to KPMG's concurrent VenturePulse analysis covering the same period, 19 deals collectively raised $212.3 million; however, just three transactions accounted for the predominant share of activity. Fonoa, a Dublin-headquartered artificial intelligence tax operating system provider, secured the largest single investment at $110 million. CameraMatics, an AI-enabled video telematics and fleet intelligence platform, raised $56 million, while Manna, a drone delivery logistics company, closed a $50 million funding round. These three deals alone underscore a market structure increasingly skewed toward late-stage capital concentration in AI-adjacent and logistics automation sectors.
Secondary-tier activity revealed additional pockets of strength in specialized sectors. Neurent Medical led the medtech category with a €62.5 million raise, followed by Aerska, which secured €33 million in biotech funding. This bifurcation—where mega-rounds in AI and logistics coexist with selective strength in medtech and biotech—reflects institutional investors' strategic prioritization of high-TAM (total addressable market) technology and health-tech verticals.
A critical feature of Ireland's 2026 venture landscape is the outsized role of international capital. International investors accounted for 85% of total capital raised during Q1 2026, a dependency that highlights both the openness of Ireland's startup ecosystem to global funding flows and the limited availability of domestic institutional venture capital. This reliance on foreign institutional syndicates creates both opportunity and concentration risk for Irish scale-ups seeking Series A and later-stage financing.
The bifurcation between mega-round winners and the broader market reflects a structural shift in Irish venture financing: in an environment of constrained overall capital availability, institutional investors are consolidating capital among proven, late-stage cohorts rather than distributing capital across a broader portfolio of emerging companies. This dynamic suggests that mid-market and early-stage Irish startups outside the AI, logistics, and specialized health-tech sectors may face materially reduced access to venture capital in 2026 and beyond.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.